SRR8518343
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290905 | — | — | 0.940 |
| 2 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.940 |
| 3 | BS_A87NPZAP | medulloblastoma | — | 0.940 |
| 4 | BS_D0RDN4K5 | Embryonal tumors | — | 0.939 |
| 5 | BS_4W68NV3M | medulloblastoma | — | 0.938 |
| 6 | C3N-03886 | — | cohortMD1 | 0.934 |
| 7 | BS_3NWQXPQV | medulloblastoma | — | 0.933 |
| 8 | SRR8526719 | — | cohortMD1 | 0.933 |
| 9 | BS_W9AT0MR7 | medulloblastoma | — | 0.933 |
| 10 | BS_BA6AZWB3 | medulloblastoma | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |